Some goals reached
The José Carreras Foundation supports scientific research as a means of finding a definitive cure for blood diseases. Thanks to recent scientific advances, for example, the treatment of chronic mylogeneous leukaemia has seen significant improvements, thanks to Imatinib (Glivec), created and patented by the pharmaceutical company Novartis, which has seen response rates of around 90%.
In parallel to this, maintenance treatment with Rituximab (MabThera), commercialized by Roche laboratories, has improved progression-free survival in patients with recurring Follicular Non-Hodgkin's Lymphoma, that respond to treatment by induction. This procedure has been shown not only to delay the appearance of relapses of the disease, but, more importantly, to reduce by 50% the risk of death from this type of cancer, previously considered incurable.